Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

Editor

Personal info

View

About

Terms

Javascript disabled

Please enable Javascript support in your browser to use this application.

Instructions on how to enable JavaScript on different browsers can be found here: http://www.google.com/support/bin/answer.py?answer=23852.

[edit this page]

MeSH Review:

Nevi and Melanomas

Massi, D. et al., Fullen, D.R. et al., Shelly, S. et al., Krengel, S. et al., Bertalot, G. et al., et al.

Fullen, Zhu, Thomas, Su, Krengel, Grotelüschen, Bartsch, Tronnier, Baldi, Santini, Russo, Catricalà, Amantea, Picardo, Tatangelo, Botti, Dragonetti, Murace, Tonini, Natali, Baldi, Paggi,

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Nevi and Melanomas

PAR-1 was significantly overexpressed in atypical nevi and melanomas in comparison with common melanocytic nevi [1].
An activating mutation in codon 599 of BRAF has been identified in approximately 60% of human cutaneous nevi and melanomas, but not melanomas of mucosal origin [2].

High impact information on Nevi and Melanomas

PAR-2 was strongly and diffusely expressed by immunohistochemistry in all melanocytic lesions, with no statistically significant differences between nevi and melanomas [1].
S100A6 protein expression is different in Spitz nevi and melanomas [3].
Significant decreases in Apaf-1 expression was observed when comparing nevi and melanomas (chi-square = 33.719; P < 0.0001) [4].
p53 Protein expression in nevi and melanomas [5].
Previous studies have yielded conflicting results on whether human telomerase RNA (hTER) expression differs in nevi, atypical nevi and melanomas using polymerase chain reaction-based telomeric repeat amplification protocol or in situ hybridization assays [6].

Gene context of Nevi and Melanomas

RESULTS: In both nevi and melanomas, E-cadherin expression in melanocytic cells decreased, following a gradient from junctional to deeper dermal localization [7].
The immunohistochemical analysis revealed a significant difference in APAF-1 staining between nevi and melanomas [8].
Similarly to immunohistochemical results, PAR-1 mRNA expression was significantly higher in atypical nevi and melanomas in comparison with common nevi and controls [1].
We now document the consistent immunoreactivity for LMP1 in 90% of 65 nevi and melanomas, using the monoclonal antibody cocktail CS1-4 [9].
Expression of p-27 (kip1) in nevi and melanomas [10].

References

Expression of protease-activated receptors 1 and 2 in melanocytic nevi and malignant melanoma. Massi, D., Naldini, A., Ardinghi, C., Carraro, F., Franchi, A., Paglierani, M., Tarantini, F., Ketabchi, S., Cirino, G., Hollenberg, M.D., Geppetti, P., Santucci, M. Hum. Pathol. (2005) [Pubmed]
Exon 15 BRAF mutations are uncommon in canine oral malignant melanomas. Shelly, S., Chien, M.B., Yip, B., Kent, M.S., Theon, A.P., McCallan, J.L., London, C.A. Mamm. Genome (2005) [Pubmed]
S100A6 protein expression is different in Spitz nevi and melanomas. Ribé, A., McNutt, N.S. Mod. Pathol. (2003) [Pubmed]
Decreased expression of Apaf-1 with progression of melanoma. Mustika, R., Budiyanto, A., Nishigori, C., Ichihashi, M., Ueda, M. Pigment Cell Res. (2005) [Pubmed]
p53 Protein expression in nevi and melanomas. Cristofolini, M., Boi, S., Girlando, S., Zumiani, G., Cristofolini, P., Dalla Palma, P., Doglioni, C., Barbareschi, M. Archives of dermatology. (1993) [Pubmed]
hTERT expression in melanocytic lesions: an immunohistochemical study on paraffin-embedded tissue. Fullen, D.R., Zhu, W., Thomas, D., Su, L.D. J. Cutan. Pathol. (2005) [Pubmed]
Cadherin expression pattern in melanocytic tumors more likely depends on the melanocyte environment than on tumor cell progression. Krengel, S., Grotelüschen, F., Bartsch, S., Tronnier, M. J. Cutan. Pathol. (2004) [Pubmed]
Analysis of APAF-1 expression in human cutaneous melanoma progression. Baldi, A., Santini, D., Russo, P., Catricalà, C., Amantea, A., Picardo, M., Tatangelo, F., Botti, G., Dragonetti, E., Murace, R., Tonini, G., Natali, P.G., Baldi, F., Paggi, M.G. Exp. Dermatol. (2004) [Pubmed]
Immunoreactivity for latent membrane protein 1 of Epstein-Barr virus in nevi and melanomas is not related to the viral infection. Bertalot, G., Biasi, M.O., Gramegna, M., Askaa, J., Dell'Orto, P., Viale, G. Virchows Arch. (2000) [Pubmed]
Expression of p-27 (kip1) in nevi and melanomas. Morgan, M.B., Cowper, S.E. The American Journal of dermatopathology. (1999) [Pubmed]

Contributions to this collaborative article are from individual authors of WikiGenes or mined by the WikiGenes Data Mining Engine from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.About WikiGenes Open Access Licence Privacy Policy Terms of Use apsburg

The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.